Cytokeratin 19 fragment/carcinoembryonic antigen ratio in pleural effusion is a useful marker for detecting malignant pleural mesothelioma

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4343-4346

  Suzuki, Hidekazu ^a   Hirashima, Tomonori ^a   Kobayashi, Masashi ^a   Sasada, Shinji ^a   Okamoto, Norio ^a   Uehara, Nobuko ^a   Tamiya, Motohiro ^a   Matsuura, Yuka ^a   Morishita, Naoko ^a   Kawase, Ichiro ^a  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

Diagnosis; Receiver operating characteristic curve; Tumour marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

AGED; ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; LOCAL ANESTHESIA; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THORACOSCOPY;

AGED; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; IMMUNOASSAY; KERATIN-19; LUMINESCENT MEASUREMENTS; MALE; MESOTHELIOMA; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 78650246612     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ and Cibas ES: The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 111: 106-109, 1997.
2. Leung AN, Muller NL and Miller RR: CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol 154: 487-492, 1990.
3. Satoh H, Sumi M, Yagyu H, Ishikawa H, Suyama T, Naitoh T, Saitoh T and Hasegawa S: Clinical evaluation of CYFRA 21-1 in malignant pleural fluids. Oncology 52: 211-214, 1995.
4. Toumbis M, Rasidakis A, Passalidou E, Kalomenidis J, Alchanatis M, Orphanidou D and Jordanoglou J: Evaluation of CYFRA 21-1 in malignant and benign pleural effusions. Anticancer Res 16: 2101-2104, 1996.
5. Romero S, Fernandez C, Arriero JM, Espasa A, Candela A, Martin C and Sanchez-Paya J: CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J 9: 17-23, 1996.
6. Salama G, Miedouge M, Rouzaud P, Mauduyt MA, Pujazon MC, Vincent C, Carles P and Serre G: Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br J Cancer 77: 472-476, 1998.
7. Lai RS, Chen CC, Lee PC and Lu JY: Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion. Jpn J Clin Oncol 29: 421-424, 1999.
8. Miedouge, M, Rouzaud P, Salama G, Pujazon MC, Vincent C, Mauduyt MA, Reyre J, Carles P and Serre G: Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer 81: 1059-1065, 1999.
9. Alatas F, Alatas O, Metintas M, Colak O, Harmanci E and Demir S: Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 31: 9-16, 2001.
10. Dejsomritrutai W, Senawong S and Promkiamon B: Diagnostic utility of CYFRA 21-1 in malignant pleural effusion. Respirology 6: 213-216, 2001.
11. Porcel JM, Vives M, Esquerda A, Salud A, Perez B and Rodriguez-Panadero F: Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 126: 1757-1763, 2001.
12. Lee JH and Chang JH: Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest 128: 2298-2303, 2005.
13. Shitrit D, Zingerman B, Shitrit AB, Shlomi D and Kramer MR: Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 10: 501-507, 2005.
14. Paganuzzi M, Onetto M, Marroni P, Filiberti R, Tassara E, Parodi S and Felletti R: Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 119: 1138-1142, 2001.
15. Pettersson T, Froseth B, Riska H and Klockars M: Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 94: 1037-1039, 1988.
16. Sasada S, Kawahara K, Kusunoki Y, Okamoto N, Iwasaki T, Suzuki H, Kobayashi M, Hirashima T, Matsui K, Ohta M and Miyazawa T: A new electrocautery pleural biopsy technique using an insulated-tip diathermic knife during semirigid pleuroscopy. Surg Endosc 23: 1901-1907, 2009.
17. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, Devos P, Chahine B, Porte H and Lassalle P: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173: 1155-1160, 2006.
18. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C and Wali A: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353: 1564-1573, 2005.